EndoPAT Main

What if you could identify high risk patients at the earliest stage of their
cardiovascular disease - would you treat them differently?

 

 

EndoPAT - A Personalized Window to Your Patients’ Arterial Health

EndoPAT only FDA-cleared non-invasive assessment of Endothelial Dysfunction (arterial health), is a functional test for early detection of underlying disease progression. It offers both prevention of re-admission, as well as early prevention of diseases. Endothelial Dysfunction is the earliest detectable stage of atherosclerosis and cardiovascular disease. Read More

The fragmented, disturbed sleep of many middle-aged adults can often be the result of sleep apnea, one of the most dangerous of all sleep disturbances...

Read More

PAT technology is a non-invasive window to the cardiovascular system and autonomic nervous system. PeripheralArterial Tone (PAT) signal is a proprietary technology used for non-invasively measuring arterial tone changes in peripheral arterial beds.

Read More

For more than a decade, endothelial dysfunction has been recognized by the medical community as the critical junction between risk factors and clinical disease. It is the earliest detectable stage of cardiovascular disease. Furthermore, it is treatable, and unlike the atherosclerotic plaque that it causes, it is even reversible.

Read More

According to American Heart Association* over 50% of coronary deaths had no previous symptoms and roughly 50% of heart attacks were not considered “high risk” patients. Demonstrated in multiple clinical studies, EndoScore (the EndoPAT test result) was proven ...

Read More

PAT technology is a non-invasive window to the cardiovascular system and autonomic nervous system. PeripheralArterial Tone (PAT) signal is a proprietary technology used for non-invasively measuring arterial tone changes in peripheral arterial beds. The PAT signal is measured from the fingertip by recording finger arterial pulsatile volume changes.

Read More

Information developed for commonly asked reimbursement questions regarding cardiology, endothelial dysfunction, PAT technology and more

Read More

Heart disease is not gender neutral, according to findings from the Women’s Ischemia Syndrome Evaluation (WISE) study, the landmark investigation into ischemic heart disease in women. Discoveries from the WISE study suggest that many women have coronary micro-vascular dysfunction that is not detected by standard diagnostic procedures and therefore goes unrecognized and untreated.

Read More


EndoPAT Resources

FAQ | Downloads | Videos